Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer
JTO Clin Res Rep
.
2022 Feb;3(2):100269.
doi: 10.1016/j.jtocrr.2021.100269.
Epub 2021 Dec 23.
Authors
Upal Basu Roy
1
,
Anne-Marie Baird
2
,
Andrew Ciupek
3
,
Jesme Fox
4
,
Eugene Manley Jr
5
,
Kim Norris Xx
6
,
Giorgio V Scagliotti
7
,
Heather A Wakelee
8
,
Tetsuya Mitsudomi
9
,
Russell C Clark
10
,
Renee Arndt
10
,
Fred R Hirsch
11
,
Paul A Bunn
12
,
Matthew P Smeltzer
13
Affiliations
1
LUNGevity Foundation, Bethesda, Maryland.
2
Lung Cancer Europe and Trinity College, Dublin, Ireland.
3
GO2 Foundation for Lung Cancer, Washington, District of Columbia.
4
Roy Castle Lung Cancer Foundation, Liverpool, United Kingdom.
5
Lung Cancer Research Foundation, New York, New York.
6
Lung Cancer Foundation of America, New Ulm, Minnesota.
7
A.O.U. San Luigi Gonzaga Hospital, University of Torino, Orbassano, Italy.
8
Stanford University, Palo Alto, California.
9
Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
10
Cancer Technology Applications, LLC, San Diego, California.
11
Icahn School of Medicine at Mount Sinai, New York, New York.
12
University of Colorado School of Medicine, Aurora, Colorado.
13
Division of Epidemiology, Biostatistics, and Environmental Health, School of Public Health, University of Memphis, Memphis, Tennessee.
PMID:
34961851
PMCID:
PMC8695593
DOI:
10.1016/j.jtocrr.2021.100269
No abstract available